Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Roe

Showing results (151-160 of 166) with videos related to

Pageof 17
Sort By:
Microbiology Spectrum|March 6, 2023
Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron SubvariantsTiffany L Roe, Tyler Brady, Nicolette Schuko, et al.
International Journal of Epidemiology|January 1, 1997
Validation of dietary assessment methods in the UK arm of EPIC using weighed records, and 24-hour urinary nitrogen and potassium and serum vitamin C and carotenoids as biomarkersS A Bingham, C Gill, A Welch, et al.
Ophthalmology|September 6, 2001
Evidence for genetic heterogeneity within eight glaucoma families, with the GLC1A Gln368STOP mutation being an important phenotypic modifierJ E Craig, P N Baird, D L Healey, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 12, 2018
Pervasive iron limitation at subsurface chlorophyll maxima of the California CurrentShane L Hogle, Christopher L Dupont, Brian M Hopkinson, et al.
Microbiology Spectrum|August 22, 2022
Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance MonitoringTyler Brady, Tianhui Zhang, Kevin M Tuffy, et al.
The Journal of Infectious Diseases|June 6, 2023
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant VariantsKevin M Tuffy, Bahar Ahani, Anastasia A Aksyuk, et al.
Infectious Diseases and Therapy|November 2, 2023
Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)Gustavo H Kijak, Bahar Ahani, Douglas Arbetter, et al.
Journal of Dietary Supplements|October 25, 2024
Developing a Screening Strategy to Identify Hepatotoxicity and Drug Interaction Potential of BotanicalsAmy L Roe, Julie Krzykwa, Angela I Calderón, et al.
Genetics|December 5, 2000
Extragenic suppressors of the nimX2(cdc2) mutation of Aspergillus nidulans affect nuclear division, septation and conidiationS L McGuire, D L Roe, B W Carter, et al.
Molecular Ecology|March 20, 2013
Paths to selection on life history loci in different natural environments across the native range of Arabidopsis thalianaAlexandre Fournier-Level, Amity M Wilczek, Martha D Cooper, et al.
Pageof 17

Showing results (151-160 of 166) with videos related to

Sort By:
Pageof 17
Microbiology Spectrum|March 6, 2023
Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron SubvariantsTiffany L Roe, Tyler Brady, Nicolette Schuko, et al.
International Journal of Epidemiology|January 1, 1997
Validation of dietary assessment methods in the UK arm of EPIC using weighed records, and 24-hour urinary nitrogen and potassium and serum vitamin C and carotenoids as biomarkersS A Bingham, C Gill, A Welch, et al.
Ophthalmology|September 6, 2001
Evidence for genetic heterogeneity within eight glaucoma families, with the GLC1A Gln368STOP mutation being an important phenotypic modifierJ E Craig, P N Baird, D L Healey, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 12, 2018
Pervasive iron limitation at subsurface chlorophyll maxima of the California CurrentShane L Hogle, Christopher L Dupont, Brian M Hopkinson, et al.
Microbiology Spectrum|August 22, 2022
Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance MonitoringTyler Brady, Tianhui Zhang, Kevin M Tuffy, et al.
The Journal of Infectious Diseases|June 6, 2023
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant VariantsKevin M Tuffy, Bahar Ahani, Anastasia A Aksyuk, et al.
Infectious Diseases and Therapy|November 2, 2023
Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)Gustavo H Kijak, Bahar Ahani, Douglas Arbetter, et al.
Journal of Dietary Supplements|October 25, 2024
Developing a Screening Strategy to Identify Hepatotoxicity and Drug Interaction Potential of BotanicalsAmy L Roe, Julie Krzykwa, Angela I Calderón, et al.
Genetics|December 5, 2000
Extragenic suppressors of the nimX2(cdc2) mutation of Aspergillus nidulans affect nuclear division, septation and conidiationS L McGuire, D L Roe, B W Carter, et al.
Molecular Ecology|March 20, 2013
Paths to selection on life history loci in different natural environments across the native range of Arabidopsis thalianaAlexandre Fournier-Level, Amity M Wilczek, Martha D Cooper, et al.
Pageof 17